U.S. Markets closed

bioMérieux S.A. (BIM.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
119.30+2.20 (+1.88%)
At close: 5:35PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close117.10
Open117.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range117.10 - 120.10
52 Week Range75.00 - 144.80
Volume118,412
Avg. Volume129,297
Market Cap15.984B
Beta (5Y Monthly)-0.08
PE Ratio (TTM)46.31
EPS (TTM)2.58
Earnings DateFeb 24, 2021
Forward Dividend & Yield0.19 (0.16%)
Ex-Dividend DateJul 14, 2020
1y Target Est68.50
  • Reuters

    French labs show how global supply bottlenecks thwart effort to ramp up testing

    Pierre-Adrien Bihl, who runs four labs that together conduct 800 tests a day in eastern France, has one explanation for what has gone wrong: a global supply chain that can't keep up. Clement ordered a new diagnostic machine from a South Korean manufacturer two months ago, which finally arrived last Friday, and now he says he can perform all tests in-house and deliver results in a day.

  • What Makes BIOMERIEUX (BMXMF) a New Buy Stock
    Zacks

    What Makes BIOMERIEUX (BMXMF) a New Buy Stock

    BIOMERIEUX (BMXMF) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • What Makes BIOMERIEUX (BMXMF) a New Strong Buy Stock
    Zacks

    What Makes BIOMERIEUX (BMXMF) a New Strong Buy Stock

    BIOMERIEUX (BMXMF) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.